All In Biotech

NDA 020870 · Noven Pharms INC

Combipatch

Estradiol, Norethindrone Acetate · Transdermal · Estrogen

Last checked: Nov 20, 2026Latest source record: Feb 15, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1998

Aug 7, 1998

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,701

351 Phase 3, 176 recruiting

FAERS reports

28

7 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: CARDIOVASCULAR DISORDERS, BREAST CANCER, ENDOMETRIAL CANCER, AND PROBABLE DEMENTIA Estrogen Plus Progestin Therapy Cardiovascular Disorders and Probable Dementia Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia. (See CLINICAL STUDIES and WARNINGS , Cardiovascular Disorders and Probable Dementia ). The Women’s Health Initiative (WHI) estrogen plus progestin substudy reported an increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg] combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo. (See CLINICAL STUDIES and WARNINGS , Cardiovascular Disorders ). The WHI Memory Study (WHIMS) estrogen plus progestin ancillary...

What it is approved for

From the label in effect Nov 10, 2026.

INDICATIONS AND USAGE CombiPatch is indicated in a woman with a uterus for: Treatment of moderate to severe vasomotor symptoms due to menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure.

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • COMBIPATCH · ESTRADIOL 0.05MG/24HR; NORETHINDRONE ACETATE 0.14MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription
  • COMBIPATCH · ESTRADIOL 0.05MG/24HR; NORETHINDRONE ACETATE 0.25MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Estradiol" as an intervention, any sponsor and status, largest first.

All 1,701 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • application site pruritus7
  • product adhesion issue7
  • application site erythema6
  • application site irritation5
  • application site inflammation3
  • application site rash3
  • drug delivery system issue3
  • invasive ductal breast carcinoma3
  • no adverse event3
  • abdominal discomfort2
  • application site discolouration2
  • application site reaction2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20141
20171
20181
20193
20201
20211
20233
20241
20252
202614

Recalls

2 FDA enforcement reports for this application.

  • Jul 30, 2021 · Class II · Ongoing

    Failed Stability Specifications; out of specification for shear.

  • Jul 30, 2021 · Class II · Ongoing

    Failed Stability Specifications; out of specification for shear.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Combipatch (Estradiol/Norethindrone Acet)

2024 spending

$5.4M

Beneficiaries

3,709

13,387 claims

Per beneficiary

$1,443

$29.89 per unit

View as table
YearSpending
2020$3,411,638
2021$3,921,844
2022$4,218,918
2023$4,681,878
2024$5,351,119

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 6,474 on PubMed

Sponsor: Noven Pharms INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.